Form 4: Aquestive Therapeutics Director John Cochran Receives Significant Stock Option Grant

Aquestive Therapeutics, Inc. (AQST) Director John Cochran reported the acquisition of 42,000 stock options, aligning his interests with shareholder value.

Summary

• John Cochran, a Director at Aquestive Therapeutics, Inc. (AQST), reported a transaction on June 11, 2025, involving the acquisition of derivative securities.
• The transaction included the acquisition of 42,000 stock options, with an exercise price of $3.41 per share.
• These options are scheduled to vest 100% on June 20, 2025, contingent upon Mr. Cochran's continuous service with the Issuer from the grant date through the vesting date.
• The expiration date for these stock options is June 11, 2035.
• Following this reported transaction, Mr. Cochran directly beneficially owns 99,486 shares of common stock and 42,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director indicates alignment of interests and is a standard compensation practice, without any negative implications disclosed.

Positives

• The grant of 42,000 stock options to Director John Cochran aligns his financial interests directly with the long-term performance and shareholder value of Aquestive Therapeutics, Inc.
• The exercise price of $3.41 per share provides a clear incentive for the director to contribute to the company's stock price appreciation.

Future Outlook

The acquired stock options are set to vest 100% on June 20, 2025, subject to the director's continuous service, indicating a future milestone for the equity compensation.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, a common practice in the biotechnology and pharmaceutical industry to incentivize and retain key personnel, aligning their interests with company performance.

Related Party Transactions

• The document details the grant of 42,000 stock options to John Cochran, a Director of Aquestive Therapeutics, Inc., which constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive for shareholders as it aligns the director's financial incentives with the company's stock performance, potentially leading to better long-term decision-making.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The vesting of 42,000 stock options on June 20, 2025, subject to continuous service.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Form 4, insider transaction, stock options, director compensation, beneficial ownership, equity grant